{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T06:10:04Z","timestamp":1735539004540,"version":"3.32.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,29]]},"DOI":"10.7759\/cureus.76594","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T05:32:06Z","timestamp":1735536726000},"source":"Crossref","is-referenced-by-count":0,"title":["Challenges in the Management of a Difficult-to-Treat Patient With Hairy Cell Leukemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Bryan","family":"Valdivia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000154","article-title":"Hairy cell leukemia: update and current therapeutic approach","volume":"22","author":"Salam L","year":"2015","unstructured":"Salam L, Abdel-Wahab O. Hairy cell leukemia: update and current therapeutic approach. Curr Opin Hematol. 2015, 22:355-61. 10.1097\/MOH.0000000000000154","journal-title":"Curr Opin Hematol"},{"key":"ref2","article-title":"Hairy cell leukemia","author":"Naing PT","year":"2023","unstructured":"Naing PT, Acharya U, Kumar A. Hairy cell leukemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.10.2839.bloodjournal85102839","article-title":"Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase","volume":"85","author":"Anthony JJ","year":"1995","unstructured":"Anthony JJ, Ernest MC, Lung TY, et al.. Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Blood. 1995, 85:2839-44. 10.1182\/blood.V85.10.2839.bloodjournal85102839","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44876","article-title":"Hairy cell leukemia: hematological and immunophenotypic profile of 13 patients","volume":"15","author":"Bhatti V","year":"2023","unstructured":"Bhatti V, Kaur G, Ahuja A, Isaacs R. Hairy cell leukemia: hematological and immunophenotypic profile of 13 patients. Cureus. 2023, 15:e44876. 10.7759\/cureus.44876","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever MR","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, et al.. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017, 129:553-60. 10.1182\/blood-2016-01-689422","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371989","article-title":"Fludarabine and rituximab for relapsed or refractory hairy cell leukemia","volume":"119","author":"Gerrie AS","year":"2012","unstructured":"Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood. 2012, 119:1988-91. 10.1182\/blood-2011-08-371989","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040956","article-title":"Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine","volume":"14","author":"Bohn JP","year":"2022","unstructured":"Bohn JP, Dietrich S. Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine. Cancers (Basel). 2022, 14:10.3390\/cancers14040956","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216135","article-title":"Venetoclax in relapsed or refractory hairy-cell leukemia","volume":"388","author":"Tiacci E","year":"2023","unstructured":"Tiacci E, De Carolis L, Santi A, Falini B. Venetoclax in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2023, 388:952-4. 10.1056\/NEJMc2216135","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.011","article-title":"Response to the therapy in hairy cell leukemia: systematic review and meta-analysis","volume":"18","author":"Andrasiak I","year":"2018","unstructured":"Andrasiak I, Rybka J, Wrobel T. Response to the therapy in hairy cell leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018, 18:392-9. 10.1016\/j.clml.2018.03.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara D","year":"2020","unstructured":"Chihara D, Arons E, Stetler-Stevenson M, et al.. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020, 38:1527-38. 10.1200\/JCO.19.02250","journal-title":"J Clin Oncol"},{"key":"ref11","article-title":"Rituximab","author":"Hanif N","year":"2024","unstructured":"Hanif N, Anwer F. Rituximab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas DA","year":"2003","unstructured":"Thomas DA, O'Brien S, Bueso-Ramos C, et al.. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003, 102:3906-11. 10.1182\/blood-2003-02-0630","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich S","year":"2012","unstructured":"Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012, 366:2038-40. 10.1056\/NEJMc1202124","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich S","year":"2016","unstructured":"Dietrich S, Pircher A, Endris V, et al.. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016, 127:2847-55. 10.1182\/blood-2015-11-680074","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini B","year":"2016","unstructured":"Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. 2016, 128:1918-27. 10.1182\/blood-2016-07-418434","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci E","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, et al.. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021, 384:1810-23. 10.1056\/NEJMoa2031298","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165795","article-title":"Extended follow up of a phase 2 study of ibrutinib in hairy cell leukemia","volume":"140","author":"Kerry AR","year":"2022","unstructured":"Kerry AR, Eric ML, Lai W. Extended follow up of a phase 2 study of ibrutinib in hairy cell leukemia. Blood. 2022, 140:6494-5. 10.1182\/blood-2022-165795","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1068981","article-title":"Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders","volume":"12","author":"Maitre E","year":"2022","unstructured":"Maitre E, Paillassa J, Troussard X. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. Front Oncol. 2022, 12:1068981. 10.3389\/fonc.2022.1068981","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504","article-title":"Next generation BTK inhibitors in CLL: evolving challenges and new opportunities","volume":"15","author":"Frustaci AM","year":"2023","unstructured":"Frustaci AM, Deodato M, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Next generation BTK inhibitors in CLL: evolving challenges and new opportunities. Cancers (Basel). 2023, 15:10.3390\/cancers15051504","journal-title":"Cancers (Basel)"},{"key":"ref20","unstructured":"Rituximab (Rituxan) desensitization protocol. (2024). Accessed. September 17, 2024: https:\/\/hemonc.org\/wiki\/Rituximab_(Rituxan)_desensitization_protocol."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/524507","article-title":"Successful desensitization of a patient with rituximab hypersensitivity","volume":"2015","author":"Ataca P","year":"2015","unstructured":"Ataca P, Atilla E, Kendir R, Bavbek S, Ozcan M. Successful desensitization of a patient with rituximab hypersensitivity. Case Reports Immunol. 2015, 2015:524507. 10.1155\/2015\/524507","journal-title":"Case Reports Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/305587-challenges-in-the-management-of-a-difficult-to-treat-patient-with-hairy-cell-leukemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T05:32:10Z","timestamp":1735536730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/305587-challenges-in-the-management-of-a-difficult-to-treat-patient-with-hairy-cell-leukemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.76594","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}